EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): Conference/Study results
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evaluating evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS) The company will also present the design a potentially pivotal, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and tolerability of evenamide as an add-on treatment in TRS An international advisory committee of TRS experts to review new results from studies 014/015 Milan, Italy, October 04, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress taking place October 7-10, 2023, at the Centre Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. Full results from all 161 patients who were randomized in study 014 and who completed six months of participation in study 015 will be presented. Study 015 is an international, randomized, open-label, rater-blinded, phase II extension study of evenamide as an add-on therapy to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS, not responding to their current antipsychotic medication. Newron presented the data from all 161 patients at the six-week time point and data from the first 100 patients randomized in study 014 who completed one-year of participation in these studies at the 34th CINP World Congress of Neuropsychopharmacology and at the 2023 SIRS Annual Congress in May 2023. The design of a potentially pivotal, international, randomized, double-blind, placebo-controlled, Phase III study aims to demonstrate the efficacy and tolerability of two doses (15 and 30 mg bid) of evenamide as an add-on treatment in TRS patients not benefiting from their current antipsychotic treatment will also be presented at the ECNP. Posters to be presented at the ECNP Congress:
About treatment-resistant schizophrenia (TRS) About study 014/015 About evenamide About Newron Pharmaceuticals For more information, please contact: UK/Europe Switzerland Germany/Europe USA
04.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1740533 04.10.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.